All In Biotech

Drug Trial Radar · NCT05729568

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

83

Actual

Start

May 15, 2023

Primary completion

Jul 2, 2024

Study completion Dec 2030

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Feb 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.

Conditions

  • HIV-1 Infection

Interventions

  • TeropavimabDrug

    Administered intravenously

  • ZinlirvimabDrug

    Administered intravenously

  • Lenacapavir TabletDrug

    Administered orally

  • Lenacapavir InjectionDrug

    Administered subcutaneously

  • Antiretroviral TherapyDrug

    Antiretroviral therapy, administered orally may include regimens such as: bictegravir/emtricitabine/tenofovir alafenamide, darunavir/cobicistat/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir lamivudine, and rilpivirine/emtricitabine/tenofovir alafenamide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 26 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot AlgorithmTime frame: Week 26

Locations

34 sites in 4 countries. Site status is shown where the registry gives one.

  • Ruane Clinical Research Group, Inc.

    Los Angeles, California

  • Mills Clinical Research

    Los Angeles, California

  • UC San Diego (UCSD) AntiViral Research Center (AVRC)

    San Diego, California

  • Optimus Medical Group

    San Francisco, California

  • University of Colorado Clinical and Translational Research Center

    Aurora, Colorado

  • Yale University; School of Medicine; AIDS Program

    New Haven, Connecticut

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Midland Florida Clinical Research Center, LLC

    DeLand, Florida

  • Can Community Health Care

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida

  • Emory University Hospital Midtown Infectious Disease Clinic

    Atlanta, Georgia

  • Infectious Disease Specialists of Atlanta

    Decatur, Georgia

  • Southhampton Healthcare, Inc

    St Louis, Missouri

  • AXCES Research Group, LLC

    Albuquerque, New Mexico

  • Montefiore Medical Center

    The Bronx, New York

  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Duke University Health Center

    Durham, North Carolina

  • Regional Center for Infectious Disease Research

    Greensboro, North Carolina

  • The Brody School of Medicine at East Carolina University

    Greenville, North Carolina

  • Rosedale Health and Wellness

    Huntersville, North Carolina

  • Prisma Health - Clinical Research Unit

    Columbia, South Carolina

  • St Jude Children's Research Hospital

    Memphis, Tennessee

  • Central Texas Clinical Research

    Austin, Texas

  • AIDS Arms, Inc. DBA Prism Health North Texas

    Dallas, Texas

  • AXCES Research Group, LLC

    El Paso, Texas

  • The Crofoot Research Center, INC

    Houston, Texas

  • Clinical Alliance for Research & Education, Infectious Diseases LLC (CARE-ID)

    Annandale, Virginia

  • East Sydney Doctors

    Darlinghurst, New South Wales, Australia

  • Holdsworth House Medical Practice

    Sydney, New South Wales, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Maple Leaf Research/Maple Leaf Medical Clinic

    Toronto, Canada

  • Clinical Research Puerto Rico

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.